Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Janux Therapeutics Inc ( (JANX) ) has shared an update.
On June 11, 2025, Janux Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, with 56,239,312 shares represented. During the meeting, stockholders elected three Class I directors to serve until the 2028 Annual Meeting, ratified Ernst & Young LLP as the independent accounting firm for 2025, approved executive compensation, and decided on the frequency of future advisory votes on executive compensation.
The most recent analyst rating on (JANX) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Janux Therapeutics Inc stock, see the JANX Stock Forecast page.
Spark’s Take on JANX Stock
According to Spark, TipRanks’ AI Analyst, JANX is a Neutral.
Janux Therapeutics Inc shows strong revenue growth and a solid balance sheet with minimal debt, which are significant positives. However, ongoing profitability challenges and negative cash flows from operations weigh heavily on the stock’s attractiveness. Technical indicators suggest a mixed outlook, with the stock trading below key moving averages despite some positive momentum signals. The valuation reflects ongoing losses, which impacts the overall score negatively.
To see Spark’s full report on JANX stock, click here.
More about Janux Therapeutics Inc
Average Trading Volume: 973,461
Technical Sentiment Signal: Sell
Current Market Cap: $1.51B
See more insights into JANX stock on TipRanks’ Stock Analysis page.